Ocular inflammation therapeutic - Tibet Rhodiola Pharmaceutical

Drug Profile

Ocular inflammation therapeutic - Tibet Rhodiola Pharmaceutical

Alternative Names: IL-1-Ra; Recombinant human interleukin-1 receptor antagonist protein - Tibet Rhodiola Pharmaceutical

Latest Information Update: 04 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tibet Rhodiola Pharmaceutical Holding Co Ltd
  • Class Eye disorder therapies; Recombinant proteins
  • Mechanism of Action Interleukin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Ocular inflammation

Most Recent Events

  • 04 Jan 2018 Phase-I clinical trials in Ocular inflammation in China (Ophthalmic)
  • 18 Dec 2017 Chengdu Rhodiola Bio-Pharmaceutical initiates enrolment in a phase I trial in Healthy volunteers in China (NCT03383276)
  • 27 Nov 2015 Clinical trials in Ocular inflammation in China (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top